Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Empiric Meropenem-based versus Ceftazidime-based Therapy for Severe Community-Acquired Pneumonia in a Retrospective Cohort Study.

Chua NG, Liew YX, Lee W, Tang SS, Zhou YP, Patel K, Kwa AL, Chlebicki MP.

Ann Acad Med Singapore. 2019 Mar;48(3):98-103. No abstract available.

2.
3.

Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.

Cai B, Cai Y, Liew YX, Chua NG, Teo JQ, Lim TP, Kurup A, Ee PL, Tan TT, Lee W, Kwa AL.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4013-22. doi: 10.1128/AAC.03064-15. Print 2016 Jul.

4.

Prospective audit and feedback in antimicrobial stewardship: is there value in early reviewing within 48 h of antibiotic prescription?

Liew YX, Lee W, Tay D, Tang SS, Chua NG, Zhou Y, Kwa AL, Chlebicki MP.

Int J Antimicrob Agents. 2015 Feb;45(2):168-73. doi: 10.1016/j.ijantimicag.2014.10.018. Epub 2014 Nov 25.

PMID:
25511192
5.

Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae.

Chua NG, Zhou YP, Tan TT, Lingegowda PB, Lee W, Lim TP, Teo J, Cai Y, Kwa AL.

J Infect. 2015 Mar;70(3):309-11. doi: 10.1016/j.jinf.2014.10.001. Epub 2014 Oct 7. No abstract available.

PMID:
25305144
6.

Echinocandin-induced eosinophilia: a case report.

Chua NG, Zhou YP, Lingegowda PB, Kwa AL, Lee W.

Scand J Infect Dis. 2014 Nov;46(11):809-12. doi: 10.3109/00365548.2014.938692. Epub 2014 Aug 14.

PMID:
25119439
7.

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure.

Zhou YP, Chua NG, Chlebicki MP, Lee WH, Kwa AL.

Case Rep Infect Dis. 2014;2014:573279. doi: 10.1155/2014/573279. Epub 2014 Jun 3.

Supplemental Content

Support Center